Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DBH | P09172 | 1/20 | 0.39 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.32 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | PIM1 | P11309 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21945242 | 0.92 | KDM4E (0.41) | DBHP2RX7ATMALDH1A1HTT | |
| SCHEMBL21945240 | 0.85 | ATM (0.41) | DBHATMALDH1A1HTTKDM4E | |
| SCHEMBL21944838 | 0.84 | DBH (0.34) | DBHATMALDH1A1KDM4ENR1I2 | |
| SCHEMBL21945791 | 0.84 | NR1I2 (0.42) | DBHATMALDH1A1HTTKDM4E | |
| SCHEMBL21945238 | 0.81 | CYP11B1 (0.34) | DBHALDH1A1HTTKDM4E | |
| SCHEMBL18005534 | 0.79 | DBH (0.41) | DBHP2RX7ATMALDH1A1HTT | |
| SCHEMBL21945142 | 0.78 | CYP11B1 (0.34) | — | |
| SCHEMBL21945148 | 0.77 | HDAC8 (0.39) | ALDH1A1HTTNR1I2NR1I3 | |
| SCHEMBL21945146 | 0.76 | HDAC3 (0.37) | ATMALDH1A1MEN1KMT2A | |
| SCHEMBL21944845 | 0.75 | KDM4E (0.39) | P2RX7ALDH1A1KDM4ESMN1; SMN2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219477-A1 | CYANOTRIAZOLE COMPOUNDS | Otsuka Pharmaceutical Co., Ltd. (JP) | 2023-08-02 | — | — | EP | disclosed |
| US-10626095-B2 | Cyanotriazole compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10626095-B2 | Cyanotriazole compounds | CS, PC, ACAT1 | DBH 2070/4885P2RX7 4488/4885ATM 675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.